Terms: = Prostate cancer AND BRD4, O60885, 23476, ENSG00000141867, HUNKI, CAP, MCAP AND Treatment
582 results:
1. Myeloid-derived suppressor cells attenuate the antitumor efficacy of radiopharmaceutical therapy using
Muralidhar A; Hernandez R; Morris ZS; Comas Rojas H; Bio Idrissou M; Weichert JP; McNeel DG
J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38663936
[TBL] [Abstract] [Full Text] [Related]
2. prostate-Specific Antigen Screening and 15-Year prostate cancer Mortality: A Secondary Analysis of the cap Randomized Clinical Trial.
Martin RM; Turner EL; Young GJ; Metcalfe C; Walsh EI; Lane JA; Sterne JAC; Noble S; Holding P; Ben-Shlomo Y; Williams NJ; Pashayan N; Bui MN; Albertsen PC; Seibert TM; Zietman AL; Oxley J; Adolfsson J; Mason MD; Davey Smith G; Neal DE; Hamdy FC; Donovan JL;
JAMA; 2024 May; 331(17):1460-1470. PubMed ID: 38581198
[TBL] [Abstract] [Full Text] [Related]
3. Co-targeting BET, CBP, and p300 inhibits neuroendocrine signalling in androgen receptor-null prostate cancer.
Choo N; Keerthikumar S; Ramm S; Ashikari D; Teng L; Niranjan B; Hedwards S; Porter LH; Goode DL; Simpson KJ; Taylor RA; Risbridger GP; Lawrence MG
J Pathol; 2024 Jun; 263(2):242-256. PubMed ID: 38578195
[TBL] [Abstract] [Full Text] [Related]
4. Variation in management of lymph node positive prostate cancer after radical prostatectomy within a statewide quality improvement consortium.
Triner D; Daignault-Newton S; Singhal U; Sessine M; Dess RT; Caram MEV; Borza T; Ginsburg KB; Lane BR; Morgan TM;
Urol Oncol; 2024 Jul; 42(7):220.e1-220.e8. PubMed ID: 38570271
[TBL] [Abstract] [Full Text] [Related]
5. Ductal, intraductal, and cribriform carcinoma of the prostate: Molecular characteristics and clinical management.
Shi Y; Wang H; Golijanin B; Amin A; Lee J; Sikov M; Hyams E; Pareek G; Carneiro BA; Mega AE; Lagos GG; Wang L; Wang Z; Cheng L
Urol Oncol; 2024 May; 42(5):144-154. PubMed ID: 38485644
[TBL] [Abstract] [Full Text] [Related]
6. Functional and oncologic outcomes of prostate capsule-sparing radical cystectomy: A systematic review and meta-analysis.
Dall CP; Mason JB; Goldman CC; Fabrizio G; Alagha EC; Chou J; Kowalczyk KJ; Agarwal PK; Stamatakis L; Krasnow RE
Urol Oncol; 2024 May; 42(5):121-132. PubMed ID: 38418269
[TBL] [Abstract] [Full Text] [Related]
7. Revolutionizing localized prostate cancer treatment: Stereotactic radiotherapy "Moroccan experience".
Naim A; Lahlou Z; Kaanouch O; Heddat A; Mansouri S
Arch Ital Urol Androl; 2024 Feb; 96(1):12104. PubMed ID: 38363238
[TBL] [Abstract] [Full Text] [Related]
8. The Ability of the STAR-cap Staging System to Prognosticate the Risk of Subsequent Therapies and Metastases After Initial treatment of M0 prostate cancer.
Sung D; Schmidt B; Tward JD
Clin Genitourin Cancer; 2024 Apr; 22(2):426-433.e5. PubMed ID: 38290900
[TBL] [Abstract] [Full Text] [Related]
9. Magnetic resonance imaging-ultrasound fusion guided focal cryoablation for men with intermediate-risk prostate cancer.
Sidana A; Tayebi S; Blank F; Lama DJ; Meyer M; Saeed Y; Tobler J; Hsu WW; Verma S
Urol Oncol; 2024 May; 42(5):158.e1-158.e10. PubMed ID: 38245407
[TBL] [Abstract] [Full Text] [Related]
10. Discovery of Novel Inhibitors of brd4 for Treating prostate cancer: A Comprehensive Case Study for Considering Water Networks in Virtual Screening and Drug Design.
Zhong H; Wang X; Chen S; Wang Z; Wang H; Xu L; Hou T; Yao X; Li D; Pan P
J Med Chem; 2024 Jan; 67(1):138-151. PubMed ID: 38153295
[TBL] [Abstract] [Full Text] [Related]
11. Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target.
Ferrari MG; Jimenez-Uribe AP; Wang L; Hoeppner LH; Murugan P; Hahm E; Yu J; Kuzel TM; Gradilone SA; Mansini AP
Oncogene; 2024 Feb; 43(7):484-494. PubMed ID: 38135694
[TBL] [Abstract] [Full Text] [Related]
12. A single-center, multi-factor, retrospective study to improve the diagnostic accuracy of primary prostate cancer using [
Lv J; Yu H; Yin H; Shi Y; Shi H
Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):919-927. PubMed ID: 37940684
[TBL] [Abstract] [Full Text] [Related]
13. A new histone deacetylase inhibitor remodels the tumor microenvironment by deletion of polymorphonuclear myeloid-derived suppressor cells and sensitizes prostate cancer to immunotherapy.
Chen Z; Yang X; Chen Z; Li M; Wang W; Yang R; Wang Z; Ma Y; Xu Y; Ao S; Liang L; Cai C; Wang C; Deng T; Gu D; Zhou H; Zeng G
BMC Med; 2023 Oct; 21(1):402. PubMed ID: 37880708
[TBL] [Abstract] [Full Text] [Related]
14. Lupeol, an androgen receptor inhibitor, enhances the chemosensitivity of prostate cancer stem cells to antiandrogen enzalutamide-based therapy.
Khan MA; Singh D; Jameel M; Maurya SK; Singh S; Akhtar K; Siddique HR
Toxicol Appl Pharmacol; 2023 Nov; 478():116699. PubMed ID: 37777120
[TBL] [Abstract] [Full Text] [Related]
15. Discovery of potent pyrrolo-pyrimidine and purine HDAC inhibitors for the treatment of advanced prostate cancer.
Moi D; Bonanni D; Belluti S; Linciano P; Citarella A; Franchini S; Sorbi C; Imbriano C; Pinzi L; Rastelli G
Eur J Med Chem; 2023 Nov; 260():115730. PubMed ID: 37633202
[TBL] [Abstract] [Full Text] [Related]
16. Functional implications and therapeutic targeting of androgen response elements in prostate cancer.
Senapati D; Sharma V; Rath SK; Rai U; Panigrahi N
Biochimie; 2023 Nov; 214(Pt B):188-198. PubMed ID: 37460038
[TBL] [Abstract] [Full Text] [Related]
17. Does testosterone replacement therapy increase the risk of conversion to treatment in patients with prostate cancer on active surveillance?
Daza J; Ahmad A; Shabir U; Jing Z; Shiekh M; Kauffman E; Guru KA; Hussein AA
Urol Oncol; 2023 Oct; 41(10):429.e1-429.e7. PubMed ID: 37423815
[TBL] [Abstract] [Full Text] [Related]
18. Estimating the Impact of the Inflation Reduction Act on the Out-of-Pocket Costs for Medicare Beneficiaries With Advanced prostate cancer.
Cortese BD; Dusetzina SB; Al Hussein Al Awamlh B; Penson DF; Chang SS; Barocas DA; Luckenbaugh AN; Scarpato KR; Moses KA; Talwar R
Urol Pract; 2023 Sep; 10(5):476-483. PubMed ID: 37409930
[TBL] [Abstract] [Full Text] [Related]
19. Long-term complications and health-related quality of life outcomes after radical prostatectomy with or without subsequent radiation treatment for prostate cancer.
Baskin A; Cowan JE; Braun A; Lonergan PE; Mohamad O; Washington SL; Zhao S; Broering JM; Cooperberg MR; Breyer BN; Carroll PR
Urol Oncol; 2023 Oct; 41(10):429.e9-429.e14. PubMed ID: 37407420
[TBL] [Abstract] [Full Text] [Related]
20. Deregulated kinase action in prostate cancer: molecular basis and therapeutic implications.
Singh N; Heemers HV
Endocr Relat Cancer; 2023 Sep; 30(9):. PubMed ID: 37279256
[TBL] [Abstract] [Full Text] [Related]
[Next]
